Web Platform Engages 3,250 People to Shape Alzheimer's Drug Research Priorities
Online portal reveals public preferences for dementia treatments, with safety concerns outweighing efficacy in drug selection decisions.
Summary
Researchers successfully engaged 3,250 people from 27 countries through an online platform to gather public input on Alzheimer's drug research. Participants ranked four repurposed medications and made treatment trade-off decisions. Metformin emerged as the most preferred option, followed by atomoxetine, isosorbide mononitrate, and levetiracetam. Notably, the probability of severe side effects was the most important factor influencing treatment preferences, more so than potential benefits. This large-scale patient and public involvement approach demonstrated that web-based engagement can effectively inform dementia research decisions at unprecedented scale, providing valuable insights into what matters most to patients and families affected by cognitive decline.
Detailed Summary
This groundbreaking study demonstrates how digital platforms can revolutionize patient involvement in medical research, particularly for age-related cognitive decline that affects millions worldwide.
Researchers created an online portal called POPPED to gather public opinions on dementia research and drug testing approaches. The platform engaged 3,250 participants across 27 countries, with 87.4% from the UK, who ranked four anonymized repurposed drugs and completed decision-making exercises about treatment trade-offs.
The results revealed clear public preferences: Metformin topped the rankings, followed by atomoxetine, isosorbide mononitrate, and levetiracetam. Most significantly, participants prioritized safety over efficacy, with severe side effect probability being the most influential factor in treatment decisions, followed by mild side effects and evidence quality. Nearly 80% of participants expressed positive attitudes toward the adaptive trial approach.
For longevity-focused individuals, this research highlights the importance of safety-first approaches to cognitive health interventions. The preference for metformin aligns with growing interest in this diabetes drug's potential neuroprotective effects. The findings suggest that when considering preventive or therapeutic interventions for brain health, the public values treatments with minimal adverse effects over potentially more effective but riskier options.
This methodology creates a reusable framework for engaging patients in research decisions, potentially accelerating the development of safer, more acceptable longevity interventions. The scale achieved through digital engagement offers a model for democratizing medical research priorities.
Key Findings
- Web-based engagement successfully gathered input from 3,250 people across 27 countries on dementia research
- Metformin was the most preferred drug among four repurposed Alzheimer's treatments tested
- Safety concerns outweighed efficacy, with severe side effects being the top decision factor
- 79.6% of participants supported the adaptive platform trial approach for drug testing
Methodology
Cross-sectional analysis of 3,250 responses from an online portal across 27 countries. Participants ranked four anonymized drugs and completed discrete choice experiments on treatment trade-offs, with analyses stratified by demographics and dementia experience.
Study Limitations
Heavy UK bias (87.4% of participants) limits global generalizability. Self-selected online participants may not represent broader population views. No long-term follow-up to assess consistency of preferences over time.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.